The global non-invasive prenatal testing (NIPT) market is dominated by the North American region. Growth in this market is driven by the high risk of chromosomal abnormalities. Advancing maternal age can cause a number of health conditions, such as decreased fertility, high blood pressure, increase in the risk of miscarriage, stillbirths, maternal deaths, and increase the risk of genetic disorders in babies as a result of the improper chromosomal division. In many countries, the average age of first-time mothers has increased. Factors like increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for non-invasive prenatal testing has also been accelerating the market growth. Development of kits and consumable sector contributes to the growth of non-invasive prenatal testing owing to increasing approvals for assays and rate of tests conducted worldwide. Surge in the use of cell-free for predicting the risk of genetic conditions in prenatal care is generating a high revenue for cell-free DNA-based NIPT segment. Diagnostics laboratories segment has been holding a dominant position in the market due to ample availability of trained laboratory technicians and well-equipped facilities. Increasing awareness of non-invasive prenatal testing and untapped market potential in emerging economies across Asia offers lucrative growth opportunities. Government is also taking initiatives to encourage the use of non-invasive prenatal testing. Huge government spending on research and development activities is one of the major factors driving the market growth. However, shortage of skilled professionals, reliability of test results, especially in obese women, are some of the factors restraining the growth of this market.
The rising competition among the key players is also providing an impetus to the market growth. Illumina, Inc. (NASDAQ: ILMN) in June’ 2021 collaborated with Next Generation Genomic to introduce VeriSeq™ NIPT Solution v2 in Southeast Asia. While prenatal screening has been available for over 30 years, conventional tests are limited in their ability to screen beyond the common trisomies of chromosomes 21, 18, and 13, but with this, healthcare providers can obtain a comprehensive view of all 23 chromosome pairs, while limiting risk to their patient. This technique will offer accurate, sensitive, and specific screening for chromosomal changes and provide more information to healthcare providers and expectant parents to empower their journey through pregnancy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis by Products and Services, Methods, Application, End Users, and Regions:
- By products and services, the market is divided into products and services, where products can be further segmented into consumables and instruments.
- Based on methods, the industry can be divided into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.
- On the basis of its application, the market can be divided into trisomy and microdeletion syndrome, among others.
- On the basis of end users, the industry is divided into diagnostic laboratories and hospitals.
- The regional markets for non-invasive prenatal testing (NIPT) include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Key Findings of the Report:
- High risk of chromosomal abnormalities is driving the growth of the non-invasive prenatal testing (NIPT) market.
- Advancing maternal age causes a number of health conditions, such as decreased fertility, high blood pressure, and increases the risk of genetic disorders in babies, boosting the demand for non-invasive prenatal testing (NIPT).
- Development of kits and the consumable sector is fuelling the demand for non-invasive prenatal testing (NIPT).
- Huge government spending on research and development activities is also propelling the market growth.
Key Offerings of the Report:
- The EMR report gives an overview of the non-invasive prenatal testing (NIPT) industry for the periods (2018-2023) and (2024-2032).
- The report also offers the historical (2018-2023) and forecasted (2024-2032) markets for the products and services, methods, application, end users, and regions of non-invasive prenatal testing (NIPT).
- The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.
The major players in the global non-invasive prenatal testing (NIPT) industry are Illumina, Inc., Thermo Fisher Scientific Corporation, PerkinElmer, Inc., Agilent Technologies, Inc., and F. Hoffmann-La Roche AG, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
About Us
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Contact Us
Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
